Answers are grounded in this paper and cite their sources.
Despite the clinical success of PD-1 blockade, the therapeutic efficacy of PD-L1 blockade in gastric cancer (GC) remains limited. Soluble PD-L1 (sPD-L1) has been proposed to function as a decoy that sequesters anti-PD-L1 antibodies, potentially contributing to therapeutic resistance. Our previous study identified an exon 5/6-skipping PD-L1 splice variant, designated PD-L1-v1, as an important source of sPD-L1 in GC. We also found that MAGOH is highly expressed in GC and participates in alternative splicing regulation. Here, we demonstrate that PD-L1-v1 acts as a soluble decoy that limits PD-L1 blocker binding to membrane-bound PD-L1 on tumor cells, thereby impairing the antitumor efficacy of PD-L1 blockade. Mechanistically, MAGOH upregulates hnRNPH1 expression, primarily by enhancing its mRNA stability, and promotes hnRNPH1-dependent exon5/6 skipping of PD-L1 pre-mRNA, thereby facilitating PD-L1-v1 and sPD-L1 generation. These findings reveal a previously unrecognized mechanism of resistance to PD-L1 blockade and highlight the MAGOH/hnRNPH1 axis as a potential strategy for improving immunotherapy efficacy in GC.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: